Price
No data yet.
Social Signal Score
Revenue
$334.13M+8616.13%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Dajun Yang
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 767
- Beta
- 0.66
- Country
- CN
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 2.15
Financials
Revenue
$334.13M+8616.1%Net Income
$-639.96MEBITDA
$-598.95MFree Cash Flow
$-787.41MEPS (diluted)
$-6.92Shares Outstanding (diluted)
92.60M+615.5%Operating Expenses
$906.30MCash & Debt
$2.47BReturn of Capital
$1.4KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $558.48M | $-1.21B | $-13.56 |
| 2024 | $980.65M | $-405.43M | $-5.36 |
| 2023 | $221.98M | $-925.64M | $-52.48 |
| 2022 | $209.71M | $-882.92M | $-53.60 |
| 2021 | $27.91M | $-782.42M | $-49.12 |
| 2020 | $12.45M | $-677.61M | $-50.24 |
| 2019 | $14.51M | $-1.48B | $-112.04 |
| 2018 | $6.81M | $-345.31M | $-26.68 |
| 2017 | $6.33M | $-118.51M | $-9.16 |
| 2016 | $7.67M | $-107.84M | $-8.32 |
Valuation
AAPGhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsglobenewswire.com·5h ago·Neutral
Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates Revenue for the first half of 2026 increased 29% year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr.
View source ↗
Earnings
Wed, Aug 19(date passed)
Consensus estimate $-0.22 per share
Typical surprise -3056.5% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Mar 24$-0.65 vs $-0.83beat
- Thu, Mar 27$-1.00 vs $0.02miss
Estimates and results for AAPG via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AAPG officers and directors.
No open-market trades in the recent filings. All 72 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
72 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.